Page 1

AVITA MEDICAL AVITA Medical Announces Positive PermeaDermⓇ Study Results Demonstrating 70 % Economic Advantage over Allograft and Comparable Clinical Outcomes August 18 , 2026 • Primary endpoint achieved , demonstrating a 70 % economic advantage over allograft based on product cost per percent total body surface area treated ( p < 0.001 ) • 96 % reduction in preparation time and comparable clinical outcomes to allograft including graft take , wound healing , and safety • Multi - center randomized controlled study supports PermeaDerm as a clinically comparable , economically advantaged alternative to allograft for wound temporization with off - the - shelf availability and no requirements for thawing , meshing , or tissue tracking logistics • Management to host Key Opinion Leader webinar at 4:30 p.m. ET on August 18 VALENCIA , Calif . , Aug. 18 , 2026 ( GLOBE NEWSWIRE ) -- AVITA Medical® , Inc. ( NASDAQ : RCEL , ASX : AVH ) , a leading therapeutic acute wound care company , today announced positive results from its multicenter , randomized controlled PermeaDerm - I clinical study demonstrating PermeaDermⓇ , a biosynthetic wound matrix , delivered clinically comparable outcomes to cadaveric allograft while reducing product cost by 70 % . The study met its primary endpoint , demonstrating statistically significant superiority ( p < 0.001 ) for mean cost per percent total body surface area ( % TBSA ) treated . Mean treatment cost was $ 148.70 for every 1 % TBSA treated with PermeaDerm compared with $ 497.10 for allograft , representing a savings of approximately $ 348 per % TBSA . As an off - the - shelf product , PermeaDerm reduced preparation time by 95.7 % compared with allograft by eliminating tissue tracking , thawing , and meshing , while maintaining comparable application time in the operating room . Clinical outcomes were comparable between treatment groups . Approximately 94 % of PermeaDerm patients achieved at least 95 % graft take one week following autografting , comparable to allograft , and all patients in both groups achieved 95 % or greater wound healing by eight weeks . No adverse events were attributed to PermeaDerm during the study . " Temporary wound coverage is a critical step between excision and definitive closure when a wound bed is not yet ready for autograft placement , " said Anju Saraswat , MD , Associate Burn Director and Assistant Professor of Surgery at Atrium Health Wake Forest Baptist Burn Center and study investigator . " These results demonstrate that PermeaDerm provided clinical performance comparable to allograft with the added benefit of product transparency enabling direct visualization of the wound bed . By eliminating tissue bank logistics and preparation time , PermeaDerm offers a more efficient approach to wound temporization without any compromise to healing outcomes and reducing cost . " " The PermeaDerm - l study establishes compelling clinical and economic evidence supporting PermeaDerm as a modern alternative to allograft , " said Cary Vance , President and Chief Executive Officer of AVITA Medical . " By combining comparable clinical performance with meaningful economic value and a simpler workflow , we believe PermeaDerm addresses an important need for hospitals while strengthening AVITA's differentiated acute wound care portfolio . " The randomized controlled study enrolled 40 patients across 11 U.S. burn centers with wounds involving up to 30 % TBSA eligible . Following excision , patients were randomized to receive either PermeaDerm or cadaveric allograft during the temporization period before definitive split - thickness skin grafting . At final follow - up , all responding investigators and patients reported satisfaction , with responses rated as satisfied or very satisfied . Virtual Analyst and Investor Event AVITA Medical will host a Key Opinion Leader webinar featuring Dr. Anju Saraswat , Associate Burn Director and Assistant Professor of Surgery at Atrium Health Wake Forest Baptist Burn Center and Dr. Christina Sharon , Burn and Acute Care Surgeon , Burn Center Director at Baton Rouge General , Baton Rouge , Louisiana to review the PermeaDerm - l clinical data and discuss clinical experience using PermeaDerm on Tuesday , August 18 , 2026 , at 4:30 p.m. Eastern Time ( Wednesday , April 19 , 2026 , at 6.30 a.m. Australian Eastern Standard Time ) . Direct webcast link : https://edge.media-server.com/mmc/p/mutcdcpe To participate by phone , please register in advance to receive dial - in details and a personal PIN : https://register-conf.media-server.com/register/B15acf2c543d9d4f8490ea42e28ae998e1 A replay of the webcast will be available shortly after the event under the Events & Presentations section of the AVITA Medical website at :